

PERSONAL INFORMATION

Bjorg Bolstad

WORK EXPERIENCE

September 2015–Present

Senior adviser

Norwegian Medicines Agency (Norway)

January 2015–September 2015

Senior Director Clinical Development

Nordic Nanovector ASA (Norway)

January 2011–December 2014

Chief Clinical Officer

Nordic Nanovector ASA (Norway)

January 2006–December 2010

Director Clinical Development

Algeta ASA (Norway)

February 2003–December 2005

Clinical Trial Manager

Algeta ASA (Norway)

September 1999–January 2003

Clinical Trial Manager

PhotoCure ASA (Norway)

September 1989–August 1999

Clinical Research Coordinator

Nycomed Imaging AS (Norway)

March 1988–August 1989

Regulatory Officer

Collett-Marwell Hauge AS (Norway)

EDUCATION AND TRAINING

August 1987–December 1987

Practical-pedagogic education

University of Oslo (Norway)

January 1984–May 1987

Cand. Scient. (MSc)

University of Oslo (Norway)

General Physiology

August 1979–December 1983

Cand. Mag.

University of Oslo (Norway)

Mathematics, Chemistry and Biology

ADDITIONAL INFORMATION

Expertise

Human domain; Clinical (Oncology, Immunology, Radiology), Safety and GCP. Clinical operations, Clinical programme development, Clinical studies. Experience with clinical development of contrast agents for image evaluations, photodynamic therapy, radiopharmaceuticals and radioimmunotherapy.

Publications

- a) Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases.
Nilsson S, Franzén L, Parker C, Tyrrell C, Blom R, Tennvall J, Lennernäs B, Petersson U, Johannessen DC, Sokal M, Pigott K, O'Bryan-Tear CG, Thuresson M, Bolstad B, Bruland ØS.
Clin Genitourin Cancer. 2013 Mar;11(1):20-6. doi: 10.1016/j.clgc.2012.07.002. Epub 2012 Sep 26.
- b) Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.
Nilsson S, Franzén L, Parker C, Tyrrell C, Blom R, Tennvall J, Lennernäs B, Petersson U, Johannessen DC, Sokal M, Pigott K, Yachnin J, Garkavij M, Strang P, Harmenberg J, Bolstad B, Bruland OS.
Lancet Oncol. 2007 Jul;8(7):587-94.
- c) Assessment of left ventricular wall motion and delineation of the endocardial border after intravenous injection of Infoson during dobutamine stress echocardiography.
Ikonomidis I, Holmes E, Narbuvoold H, Bolstad B, Muan B, Nihoyannopoulos P.
Coron Artery Dis. 1998;9(9):567-76.
- d) Main results of the first comparative clinical studies on Visipaque.
Grynne BH, Nossen JO, Bolstad B, Borch KW.
Acta Radiol Suppl. 1995;399:265-70. Review.
- e) Intra-arterial digital subtraction angiography with isotonic dimeric (iodixanol) and monomeric (iohexol) nonionic contrast media: radiographic, clinical and neurophysiological evaluation.
Hekster RE, Morré HH, Cleyndert P, Zapletal J, Sinnige LF, Bolstad B, Keetlapper Y.
Neuroradiology. 1995 Jan;37(1):48-50.
- f) Iodixanol in femoral arteriography. A randomized, double-blind, phase III, parallel study with iodixanol 270 mg I/ml and iohexol 300 mg I/ml.
Thorstensen O, Albrechtsson U, Calissendorff B, Lárusdóttir H, Norgren L, Tengvar M, Bolstad B, Aspelin P.
Acta Radiol. 1994 Nov;35(6):629-31.
- g) Iodixanol in cardioangiography. A double-blind parallel comparison between iodixanol 320 mg I/ml and ioxaglate 320 mg I/ml.
Tveit K, Bolz KD, Bolstad B, Haugland T, Berg KJ, Skjaerpe T, Kloster YF.
Acta Radiol. 1994 Nov;35(6):614-8.
- h) Iodixanol and ioxaglate in cardioangiography: a double-blind randomized phase III study.
Andersen PE, Bolstad B, Berg KJ, Justesen P, Thayssen P, Kloster YF.
Clin Radiol. 1993 Oct;48(4):268-72.
- i) Iodixanol in abdominal digital subtraction angiography. A randomized, double-blind, parallel trial with iodixanol and iohexol.
Singh K, Sundgren R, Bolstad B, Björk L, Lie M.
Acta Radiol. 1993 May;34(3):242-5.
- j) Safety and tolerability of iodixanol. A dimeric, nonionic contrast medium: an emphasis on European clinical phases I and II.
Bolstad B, Borch KW, Grynne BH, Lundby B, Nossen JO, Kloster YF, Kristoffersen DT, Andrew E.
Invest Radiol. 1991 Nov;26 Suppl 1:S201-4; discussion S208.

Projects

Memberships

Other Relevant Information